Use of Rosuvastatin 10 mg was found to provide CV benefits and lowers blood pressure (BP) in those with elevated systolic BP for at least 3 years even after its stoppage in people without CV disease representing a legacy effect, outcomes of 8.7 years of an extended follow-up study of Heart Outcomes Evaluation Prevention (HOPE)-3 trial portrayed.

In order to study if the CV events lowering benefits of Rosuvastatin 10 mg daily is sustained or improved or attenuated even after its cessation,  the patients with elevated systolic BP were called to participate in this 8.7 years ( 5.6 years plus 3.1 more years of observation). The first co-primary outcome comprised of MACE-1 i.e. myocardial infarction, stroke, or CV death. The second co-primary outcome comprised of MACE-2 i.e. MACE-1 along with resuscitated cardiac arrest, heart failure, or coronary revascularization.

Out of 11,994 surviving individuals of the HOPE-3 study, 9326 (78%) participated in this study. Compared with placebo, the individuals initially randomized to rosuvastatin had a 20% and 17% additional reduction in MACE-1 and MACE-2, respectively during a follow-up of 8.7 years. During the active or after the trial observation period, no BP lowering benefit was perceived, but MACE-1 was reduced by 24% in individuals with high systolic BP over the total follow-up period.